Aravive, Inc. Profile Avatar - Palmy Investing

Aravive, Inc.

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets…

Biotechnology
US, Houston [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Aravive, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of ARAV's Analysis
CIK: 1513818 CUSIP: 03890D108 ISIN: US03890D1081 LEI: - UEI: -
Secondary Listings
ARAV has no secondary listings inside our databases.